Company is immediately taking steps, including an approximately 73% reduction in workforce, to preserve cash.
All entries for: Layoffs
January 9, 2025
IGM Biosciences
Layoffs
Mountain View, CA
201-500 employees
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
January 9, 2025
Intellia Therapeutics
Layoffs
Cambridge, MA
501-1,000 employees
Anticipated cost savings, including a net workforce reduction of approximately 27% in 2025, support company operations into 1H 2027 and through anticipated, first commercial launch in the U.S.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
January 8, 2025
Galapagos
Discontinued Research, Layoffs
Cambridge, MA
1,001-5,000 employees
“To advance its goal of becoming a global leader in cell therapy in oncology, Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over its small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.”
2 Discontinued Research Programs
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Small Molecule
January 8, 2025
Galapagos
Layoffs
Cambridge, MA
1,001-5,000 employees
Galapagos intends to reorganize its business to focus on long-term value creation in cell therapy in oncology. This is anticipated to lead to a reduction of approximately 300 positions.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
December 10, 2024
Belharra Therapeutics
Layoffs
San Diego, CA
1-50 employees
“San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed…
The employee cuts are expected to allow Belharra to extend its runway to achieve “key inflection points” while alleviating capital raise pressures, according to a spokesperson’s emailed statement to Endpoints. That spokesperson also wrote that the biotech will continue advancing its lead programs and working with partners Genentech and Sanofi.”
Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Small Molecule
December 9, 2024
AmplifyBio
Layoffs
West Jefferson, OH
201-500 employees
“AmplifyBio is cutting costs, closing its R&D and characterization services site in South San Francisco and laying off employees in its Ohio-based preclinical CRO business, a company spokesperson confirmed to Fierce Biotech in an email.”
Disease Area: Cardiology, Neurological Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
November 15, 2024
Charles Rivers Laboratories
Layoffs
Wilmington, MA
10,001-50,000 employees
“One of Massachusetts’ major life science companies, Charles River Laboratories Inc., has revealed new details on its ongoing cost-savings initiatives, stating in an earnings call that it’s “already generating significant savings.”
The Wilmington-based company revealed a strategic turnaround plan in Q4 of 2023, announcing it would cut more than 6% of its workforce, and has continued to reduce staffing levels through Q3 of 2024, the Boston Business Journal reported.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
October 21, 2024
Takeda
Layoffs
Cambridge, MA
10,001-50,000 employees
“Takeda is laying off dozens of employees in Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) alert filed with the state late last week. The layoff process kicked off in late September and will run through March of next year, according to state records.
“While the WARN alert states that 79 employees across the two sites are set to face cuts, the final number “is not clear at this time” and will depend on potential “redeployment opportunities,” according to a detailed filing cited by Boston Business Journal.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
September 24, 2024
Bluebird Bio
Layoffs
Somerville, MA
201-500 employees
Announced a restructuring to optimize the company’s cash structure…The initiative includes a reduction in the Company’s workforce of approximately 25%.
Disease Area: Rare Diseases
Drug Type: Biologic
August 14, 2024
Evotec
Layoffs
Hamburg, Germany
1,001-5,000 employees
“Evotec is having to further shrink its manufacturing footprint and has identified 400 jobs globally that could potentially get cut, with a “sizable share” set to be laid off this year, according to Wojczewski. The first round of layoffs saw 100 workers cut across the UK and US, according to the company presentation. The rest of the layoffs will be made in Germany, Italy and France, Wojczewski added.
The company has also completed the shutdown of its chemistry work at a site in Lyon, France, and is closing an API manufacturing facility in Halle, Germany.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
